JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $300
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on United Therapeutics (NASDAQ:UTHR) and raises the price target from $280 to $300.
May 21, 2024 | 4:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Jessica Fye maintains an Overweight rating on United Therapeutics and raises the price target from $280 to $300.
The raised price target and maintained Overweight rating from a reputable analyst at JP Morgan is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100